MacroGenics posts corporate overview highlighting oncology pipeline, cash runway through 2028
MGNX•Lorigerlimab clinical data
- Lorigerlimab reported a 25% ORR in 16 evaluable clear cell gynecologic cancer patients at 6 mg/kg Q3W; additional enrollment planned at 3 mg/kg.
Corporate overview and cash runway
-
MacroGenics highlighted $327 million pro forma cash and marketable securities as of June 30, 2026, with runway guidance through 2028.
-
Pipeline focus on antibody-drug conjugates, with MGC026 B7-H3 TOP1i ADC positioned for potential proof-of-concept in SCCHN.
Pipeline updates on MGC026 and MGC028
-
MGC026 Phase 1 update flagged no ILD or ocular toxicity as of July 8, 2026, with anti-tumor activity across several solid tumors.
